
Pfizer puts up $1bn to buy into Arvinas breast cancer progra...
Pfizer has pledged a whopping $1 billion upfront for rights to an Arvinas drug for breast cancer from its protein degrader platform, which harnesses cells' natural protein-denaturing machin